Trial · NCT03336645
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Response Rate | SHP615 | 80.0 | Percentage of participants | ||
| Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours | SHP615 | Sustained Absence for at least 1 hour | 68.0 | Percentage of participants | |
| Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours | SHP615 | Sustained Absence for at least 4 hours | 36.0 | Percentage of participants | |
| Percentage of Participants Who Had Sustained Absence of Seizure Activity for at Least 1, 4 and 6 Hours | SHP615 | Sustained Absence for at least 6 hours | 32.0 | Percentage of participants | |
| Number of Participants With Time to Resolution of Seizures (Convulsions) | SHP615 | 21 | Participants | ||
| Number of Participants With Time to Recovery of Consciousness | SHP615 | 19 | Participants | ||
| Percentage of Participants Who Required Additional Anticonvulsant Medication for Ongoing Status Epilepticus (SE) | SHP615 | 16.0 | Percentage of Participants | ||
| Percentage of Participants Who Failed to Respond to the Treatment With SHP615 | SHP615 | 16.0 | Percentage of participants | ||
| Concentration of SHP615 in Plasma at 10 Minutes (C10) | SHP615 | 45.2 | Standard Deviation 21.3 | nanogram per milliliter (ng/mL) | |
| Maximum Plasma Concentration (Cmax) of SHP615 | SHP615 | 78.0 | Standard Deviation 16.4 | ng/mL | |
| Area Under the Concentration-time Curve From Time Zero to 10 Minutes (AUC0-10) of SHP615 in Plasma | SHP615 | 304 | Standard Deviation 149 | min ng/mL | |
| Area Under the Concentration-time Curve From Time Zero to 60 Minutes (AUC0-60) of SHP615 in Plasma | SHP615 | 2965 | Standard Deviation 592 | min ng/mL | |
| Area Under the Concentration-time Curve From Time Zero to 180 Minutes (AUC0-180) of SHP615 in Plasma | SHP615 | 4411 | Standard Deviation 1140 | min ng/mL | |
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of SHP615 in Plasma | SHP615 | 5847 | Standard Deviation 2599 | min ng/mL | |
| Time at Maximum Concentration (Tmax) of SHP615 in Plasma | SHP615 | 20.5 | Full Range 15.5 to 28.0 | minutes | |
| Elimination Half-life (T1/2) of SHP615 in Plasma | SHP615 | 115 | Full Range 90.6 to 303 | minutes | |
| Number of Participants With Respiratory Depression | SHP615 | Persistent Decrease in Oxygen Saturation | 0 | Participants | |
| Number of Participants With Respiratory Depression | SHP615 | Increase in Respiratory Effort | 1 | Participants | |
| Number of Participants With Aspiration Pneumonia Reported as Treatment Emergent Adverse Events (TEAEs) | SHP615 | 0 | Participants | ||
| Change From Baseline in Riker Sedation-Agitation Scale at 24 Hours Post-dose | SHP615 | 2.2 | Standard Deviation 1.23 | Score on the scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03336645/results